BMY logo

Bristol-Myers Squibb (BMY) Stock

Profile

Full Name:

Bristol-Myers Squibb Company

Sector:

Healthcare

Country:

United States

IPO:

01 June 1972

Indexes:

Description:

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, licensing, manufacturing, marketing, and sale of biopharmaceutical products. Bristol-Myers pharmaceutical products are chemically synthesized or low molecular weight drugs for the following therapeutic areas: oncology; immunology with priorities in psoriasis, lupus, cancer, inflammatory bowel diseases, HIV; cardiovascular with priority in heart disease; fibrotic diseases of the lungs and liver; hepatitis B, C. The line of pharmaceuticals is represented by 10 trade brands. The Bristol-Myers company was registered in 1933 and essentially is the successor of a New York pharmaceutical manufacturer that has been in operation since 1887. Bristol-Myers' major manufacturing facilities are located in the United States, Puerto Rico, Ireland, France, and Italy.

Key Details

Price

$59.66

TTM Dividend Yield

4.06%(-14.35% YoY)

Annual Revenue

$45.01 B(-2.50% YoY)

Annual EPS

$3.86(+30.85% YoY)

Beta

0.11

Events Calendar

Earnings

Next earnings date:

Feb 06, 2025

Recent quarterly earnings:

Oct 31, 2024

Recent annual earnings:

Feb 02, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Jan 03, 2025
Splits

Next split:

N/A

Recent split:

Aug 07, 2001

Analyst ratings

Recent major analysts updates

28 Jan '25 Citigroup
Neutral
08 Jan '25 Truist Securities
Buy
16 Dec '24 Jefferies
Buy
15 Nov '24 Wolfe Research
Peer Perform
12 Nov '24 Morgan Stanley
Underweight
12 Nov '24 Leerink Partners
Outperform
12 Nov '24 Citigroup
Neutral
12 Nov '24 BMO Capital
Market Perform
01 Nov '24 BMO Capital
Market Perform
25 Oct '24 Citigroup
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
BMY
zacks.com03 February 2025

The CHMP suggests that Bristol Myers' Opdivo combined with Yervoy should be approved for the initial treatment of hepatocellular carcinoma, as well as Breyanzi for patients with relapsed or refractory follicular lymphoma.

Should Bristol Myers Stock Be in Your Portfolio Pre-Q4 Earnings?
Should Bristol Myers Stock Be in Your Portfolio Pre-Q4 Earnings?
Should Bristol Myers Stock Be in Your Portfolio Pre-Q4 Earnings?
BMY
zacks.com03 February 2025

BMY aims to improve its business by relying on the successful launch of new medications. Recent positive news from regulators is also a good sign for the company's stock.

What Analyst Projections for Key Metrics Reveal About Bristol Myers (BMY) Q4 Earnings
What Analyst Projections for Key Metrics Reveal About Bristol Myers (BMY) Q4 Earnings
What Analyst Projections for Key Metrics Reveal About Bristol Myers (BMY) Q4 Earnings
BMY
zacks.com03 February 2025

In addition to Wall Street's predictions for Bristol Myers' (BMY) earnings, take a look at forecasts for some important metrics to better understand how the company performed in the quarter that ended in December 2024.

2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
BMY
fool.com03 February 2025

If there were a formal list of important factors for dividend investors to think about before buying a stock, the company's core business would likely be more important than its dividend yield. Still, these two aspects can work together and are not completely separate.

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
BMY
benzinga.com31 January 2025

Medicaid funding, which is about $900 billion each year and helps around 72 million people, along with the 340B program, are important areas to consider for possible changes in healthcare.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
BMY
zacks.com31 January 2025

Our Zacks Earnings ESP makes it simpler to identify stocks that are likely to exceed quarterly earnings predictions.

Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
BMY
zacks.com30 January 2025

Bristol Myers (BMY) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.

3 Cheap Dividend Stocks That Pay More Than Double the S&P 500 Average
3 Cheap Dividend Stocks That Pay More Than Double the S&P 500 Average
3 Cheap Dividend Stocks That Pay More Than Double the S&P 500 Average
BMY
fool.com29 January 2025

A lot of stocks do not provide very high returns. For example, the average yield of stocks in the S&P 500 is only 1.3%.

Why the Market Dipped But Bristol Myers Squibb (BMY) Gained Today
Why the Market Dipped But Bristol Myers Squibb (BMY) Gained Today
Why the Market Dipped But Bristol Myers Squibb (BMY) Gained Today
BMY
zacks.com27 January 2025

On the most recent trading day, Bristol Myers Squibb (BMY) closed at $60.62, which is an increase of 1.59% compared to its last closing price.

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy
BMY
businesswire.com25 January 2025

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS has shared findings from the CheckMate -8HW study.

FAQ

  • What is the primary business of Bristol-Myers Squibb?
  • What is the ticker symbol for Bristol-Myers Squibb?
  • Does Bristol-Myers Squibb pay dividends?
  • What sector is Bristol-Myers Squibb in?
  • What industry is Bristol-Myers Squibb in?
  • What country is Bristol-Myers Squibb based in?
  • When did Bristol-Myers Squibb go public?
  • Is Bristol-Myers Squibb in the S&P 500?
  • Is Bristol-Myers Squibb in the NASDAQ 100?
  • Is Bristol-Myers Squibb in the Dow Jones?
  • When was Bristol-Myers Squibb's last earnings report?
  • When does Bristol-Myers Squibb report earnings?
  • Should I buy Bristol-Myers Squibb stock now?

What is the primary business of Bristol-Myers Squibb?

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, licensing, manufacturing, marketing, and sale of biopharmaceutical products. Bristol-Myers pharmaceutical products are chemically synthesized or low molecular weight drugs for the following therapeutic areas: oncology; immunology with priorities in psoriasis, lupus, cancer, inflammatory bowel diseases, HIV; cardiovascular with priority in heart disease; fibrotic diseases of the lungs and liver; hepatitis B, C. The line of pharmaceuticals is represented by 10 trade brands. The Bristol-Myers company was registered in 1933 and essentially is the successor of a New York pharmaceutical manufacturer that has been in operation since 1887. Bristol-Myers' major manufacturing facilities are located in the United States, Puerto Rico, Ireland, France, and Italy.

What is the ticker symbol for Bristol-Myers Squibb?

The ticker symbol for Bristol-Myers Squibb is NYSE:BMY

Does Bristol-Myers Squibb pay dividends?

Yes, Bristol-Myers Squibb pays dividends. The last payment was $0.62, with an ex-dividend date on 03 January 2025

What sector is Bristol-Myers Squibb in?

Bristol-Myers Squibb is in the Healthcare sector

What industry is Bristol-Myers Squibb in?

Bristol-Myers Squibb is in the Drug Manufacturers - General industry

What country is Bristol-Myers Squibb based in?

Bristol-Myers Squibb is headquartered in United States

When did Bristol-Myers Squibb go public?

Bristol-Myers Squibb's initial public offering (IPO) was on 01 June 1972

Is Bristol-Myers Squibb in the S&P 500?

Yes, Bristol-Myers Squibb is included in the S&P 500 index

Is Bristol-Myers Squibb in the NASDAQ 100?

No, Bristol-Myers Squibb is not included in the NASDAQ 100 index

Is Bristol-Myers Squibb in the Dow Jones?

No, Bristol-Myers Squibb is not included in the Dow Jones index

When was Bristol-Myers Squibb's last earnings report?

Bristol-Myers Squibb's most recent earnings report was on 31 October 2024

When does Bristol-Myers Squibb report earnings?

The next expected earnings date for Bristol-Myers Squibb is 6 February 2025

Should I buy Bristol-Myers Squibb stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions